From: owner-ammf-digest@smoe.org (alt.music.moxy-fruvous digest) To: ammf-digest@smoe.org Subject: alt.music.moxy-fruvous digest V14 #11021 Reply-To: ammf@fruvous.com Sender: owner-ammf-digest@smoe.org Errors-To: owner-ammf-digest@smoe.org Precedence: bulk alt.music.moxy-fruvous digest Tuesday, March 28 2023 Volume 14 : Number 11021 Today's Subjects: ----------------- Want To Clear Fungus 3X Faster!? Try THIS Odd Technique ["Clear Nail Fung] ---------------------------------------------------------------------- Date: Tue, 28 Mar 2023 12:12:52 +0200 From: "Clear Nail Fungus" Subject: Want To Clear Fungus 3X Faster!? Try THIS Odd Technique Want To Clear Fungus 3X Faster!? Try THIS Odd Technique http://fedzexsurvey.today/lWQ8X0IXyCJPxgPXGUEnf3xJ8kwhHH76SeZQVFWVWG7E2yrcVQ http://fedzexsurvey.today/A607Jgqnsh54fc5xEdk68oSYnkooPhyJaKVPboIjt2d6DFWX0Q As enzymes have evolved to bind their substrates tightly, and most reversible inhibitors bind in the active site of enzymes, it is unsurprising that some of these inhibitors are strikingly similar in structure to the substrates of their targets. Inhibitors of dihydrofolate reductase (DHFR) are prominent examples. Other examples of these substrate mimics are the protease inhibitors, a therapeutically effective class of antiretroviral drugs used to treat HIV/AIDS. The structure of ritonavir, a peptidomimetic (peptide mimic) protease inhibitor containing three peptide bonds, as shown in the "competitive inhibition" figure above. As this drug resembles the peptide that is the substrate of the HIV protease, it competes with the substrate in the enzyme's active site. Enzyme inhibitors are often designed to mimic the transition state or intermediate of an enzyme-catalysed reaction. This ensures that the inhibitor exploits the transition state stabilising effect of the enzyme, resulting in a better binding affinity (lower Ki) than substrate-based designs. An example of such a transition state inhibitor is the antiviral drug oseltamivir; this drug mimics the planar nature of the ring oxonium ion in the reaction of the viral enzyme neuraminidase. However, not all inhibitors are based on the structures of substrates. For example, the structure of another HIV protease inhibitor tipranavir is not based on a peptide and has no obvious structural similarity to a protein substrate. These non-peptide inhibitors can be more stable than inhibitors containing peptide bonds, because they will not be substrates for peptidases and are less lik ------------------------------ End of alt.music.moxy-fruvous digest V14 #11021 ***********************************************